S
Stewart Gaede
Researcher at University of Western Ontario
Publications - 94
Citations - 3560
Stewart Gaede is an academic researcher from University of Western Ontario. The author has contributed to research in topics: SABR volatility model & Radiation therapy. The author has an hindex of 21, co-authored 85 publications receiving 2109 citations. Previous affiliations of Stewart Gaede include London Health Sciences Centre & Lawson Health Research Institute.
Papers
More filters
Journal ArticleDOI
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma,Robert Olson,Stephen Harrow,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,Liam Mulroy,Michael Lock,George Rodrigues,Brian Yaremko,Devin Schellenberg,Belal Ahmad,Gwendolyn H.M.J. Griffioen,Sashendra Senthi,Anand Swaminath,Neil Kopek,Mitchell Liu,Karen Moore,S. Currie,Glenn Bauman,Andrew Warner,Suresh Senan +21 more
TL;DR: SABR was associated with an improvement in overall survival, meeting the primary endpoint of this trial, but three (4·5%) of 66 patients in the SABR group had treatment-related death.
Journal ArticleDOI
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.
David A. Palma,Robert Olson,Stephen Harrow,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,Liam Mulroy,Michael Lock,George Rodrigues,Brian Yaremko,Devin Schellenberg,Belal Ahmad,Sashendra Senthi,Anand Swaminath,Neil Kopek,Mitchell Liu,Karen Moore,S. Currie,Roel Schlijper,Glenn Bauman,Joanna Laba,X. Melody Qu,Andrew Warner,Suresh Senan +23 more
TL;DR: With extended follow-up, the impact of SABR on OS was larger in magnitude than in the initial analysis and durable over time and there were no new safety signals, and S ABR had no detrimental impact on QOL.
Posted ContentDOI
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
David A. Palma,Robert Olson,Stephen Harrow,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,Liam Mulroy,Michael Lock,George Rodrigues,Brian Yaremko,Devin Schellenberg,Belal Ahmad,Sashendra Senthi,Anand Swaminath,Neil Kopek,Mitchell Liu,Karen Moore,S. Currie,Roel Schlijper,Glenn Bauman,Joanna Laba,X. Melody Qu,Andrew Warner,Suresh Senan +23 more
TL;DR: With extended follow-up, the impact of SABR on OS was larger in magnitude than in the initial analysis, and durable over time, and there were no new safety signals, and S ABR had no detrimental impact on QOL.
Journal ArticleDOI
Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
David A. Palma,Cornelis J.A. Haasbeek,George Rodrigues,Max Dahele,Michael Lock,Brian Yaremko,Robert Olson,Mitchell Liu,Jason Panarotto,Gwendolyn H.M.J. Griffioen,Stewart Gaede,Ben J. Slotman,Suresh Senan +12 more
TL;DR: An assessment of the impact of SABR on clinical outcomes and quality of life is provided to determine if long-term survival can be achieved for selected patients with oligometastatic disease, and will inform the design of a possible phase III study.
Journal ArticleDOI
Inter-observer and intra-observer reliability for lung cancer target volume delineation in the 4D-CT era
Alexander V. Louie,George Rodrigues,Jason Olsthoorn,David A. Palma,Edward Yu,Brian Yaremko,Belal Ahmad,I. Aivas,Stewart Gaede +8 more
TL;DR: Variability in TVD is a major source of error in 4D-CT treatment planning and development of measures to reduce inter-observer and intra-ob server TVD variability are necessary in order to deliver high quality radiotherapy.